Structural and molecular basis for Ebola virus neutralization by protective human antibodies

Publisher Website
Google Scholar
Abstract
Antibodies block Ebola virus entry: The recent Ebola virus outbreak in West Africa illustrates the need for both an effective vaccine and therapies to treat infected individuals. Corti et al. isolated two monoclonal antibodies from a survivor of the 1995 Kikwit outbreak and demonstrated their therapeutic efficacy in Ebola virus–infected macaques. In fact, one antibody protected macaques when it was given up to 5 days after infection. Misasi et al. solved the crystal structures of fragments of the two antibodies bound to the Ebola virus glycoprotein (GP), which mediates viral cell entry. The two antibodies targeted different regions of GP, but in both cases blocked steps required for viral entry. Science , this issue pp. 1339 & 1343
Funding Information
  • Intramural Research Program of the Vaccine Research Center
  • National Institute of Allergy and Infectious Diseases
  • NIH (NIH-5K08AI079381)
  • Boston Children's Hospital Faculty Development
  • National Institute of General Medical Sciences of the National Institutes of Health (T32GM008704)
  • 973 Program (2015CB14010102)
  • National Natural Science Foundation of China (81550001, 31470721)
  • Junior Thousand Talents Program of China (20131770418)
  • Frederick National Laboratory for Cancer Research
  • National Institutes of Health (HHSN261200800001E)